Please use this identifier to cite or link to this item:
|Title:||Selective targeting of the tumour vasculature.||Austin Authors:||Chan, Lie S;Daruwalla, Jurstine;Christophi, Christopher||Affiliation:||Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia||Issue Date:||1-Nov-2008||Publication information:||ANZ Journal of Surgery; 78(11): 955-67||Abstract:||Selective targeting of the tumour vasculature in the treatment of solid organ malignancies is an alternative to conventional chemotherapy treatment. As the tumour progressively increases in size, angiogenesis or the formation of new vasculature is essential to maintain the tumour's continual growth and survival. Therefore disrupting this angiogenic process or targeting the neovasculature can potentially hinder or prevent further tumour expansion. Many anti angiogenic agents have been investigated with many currently in clinical trials and exhibiting varied results. Vascular disrupting agents such as the Combretastatins and OXi 4503 have shown promising preclinical results and are currently being examined in clinical trials.||Gov't Doc #:||18959693||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10701||DOI:||10.1111/j.1445-2197.2008.04712.x||URL:||https://pubmed.ncbi.nlm.nih.gov/18959693||Type:||Journal Article||Subjects:||Angiogenesis Inhibitors.therapeutic use
Neoplasms.blood supply.drug therapy
Neovascularization, Pathologic.prevention & control
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 30, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.